AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson’s Icotyde, the first oral IL-23 inhibitor on the market. This ...

Protagonist Therapeutics (PTGX) shares ended the last trading session 4.7% higher at $101.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced that it has regained compliance with ...

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Shares of AbbVie ABBV fell 5.2% on Wednesday, wiping out more than $20 billion in market value. This selloff comes as ...

Bristol Myers BMY recently secured a meaningful label expansion for Sotyktu, with the FDA approving the drug for adults with ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact ...

Diamond Hill Capital, an investment management company, released its “Mid Strategy” fourth-quarter 2025 investor letter. A ...

However, it's also important that they are also comfortable and not flimsy, which is why we want to point out one particular Amazon deal. The online delivery giant has slashed the 39 percent off the ...

Amazon is constantly adding new offerings to its marketplace. We did the work of searching for the best kitchen finds of March 2026 so you don't have to.

While taking her history and vital signs, Supiano, a geriatrician at the University of Utah, saw one disturbing signal: Her blood pressure was 148/86, above normal despite her taking two medications ...

The patient initially came to see Mark Supiano in 2017 because her family was concerned about her short-term memory loss.